AUTHORS
Fnu Alnoor, MD, Peng Li, MD, PhD2, Oscar Silva, MD3, Peyman Samghabadi, MD4, Jingjing Zhang, MD, PhD5, Olga Weinberg, MD6, Karen Chisholm, MD, PhD7, Zijun Yidan xu-Monette, PhD8, Ken H. H. Young Jr, MD, PhD9, David Ng, MD, FCAP10, Robert Ohgami, MD, PhD, MBA11
AFFILIATIONS
1 University of Miami, Miami, Florida, United States
2 ARUP Laboratories, Salt Lake City, United States, Department of Pathology, Salt Lake City, Utah, United States
3 Stanford University School-Medical, Palo Alto, California, United States
4 University of California San Francisco, San Francisco, California, United States
5 University of Colorado, Aurora, Colorado, United States
6 University of Texas Southwestern Medical School, Dallas, Texas, United States
7 University of Washington, Seattle, Washington, United States
8 Duke University, Durham, North Carolina, United States
9 Duke University, Durham, North Carolina, United States
10 ARUP Laboratories, Salt Lake City, United States, Department of Pathology, Salt Lake City, Utah, United States
11 ARUP Laboratories, Salt Lake City, United States, Department of Pathology, Salt Lake City, Utah, United States
ABSTRACT
Background: Idiopathic multicentric Castleman disease (iMCD) is a heterogeneous cytokine driven lymphoproliferative disorder with incompletely defined molecular drivers. NCOA4 is the selective cargo receptor for ferritinophagy and regulates ferritin turnover, macrophage iron recycling, and iron availability for erythropoiesis. Recurrent NCOA4 alterations have been reported in iMCD, but their clinicopathologic context, relationship to germline susceptibility, and potential connection to inflammatory iron biology remain incompletely understood.
Methods: We performed a case level re-analysis of the original whole exome sequencing cohort and supplementary data from 22 patients with iMCD. NCOA4 alteration, variant allele frequency (VAF), histology, clinical features, performance status, treatment, and outcome were extracted and analyzed. We reviewed the reported evidence supporting somatic classification and assessed whether the available clinical data permitted contemporary assignment as iMCD-IPL or iMCD-TAFRO. Findings were integrated with an independent study of identical twins with candidate germline NCOA4 and TRAF3 variants and with published NCOA4 depletion macrophage transcriptomic and ferritinophagy studies.
Results: NCOA4 alterations were reported in 5 of 22 patients (23%): four recurrent p.L261F variants and one splice-site alteration. All five patients had plasma-cell-type histology. Four of five (80%) had B symptoms, effusions or ascites, and organomegaly; ECOG performance status ranged from 2 to 4. Consistent with the original gene-outcome analysis, OS24 failure was concentrated among NCOA4-altered cases (4 of 5 [80%] versus 3 of 17 [18%]; secondary Fisher’s exact P = .021). Three NCOA4 mutated patients died within 3 months, one died at 19 months, and one was alive at 28 months. VAFs clustered from 45.0% to 51.7%. Although the original study reported paired saliva-based filtering and classified the alterations as somatic, the available case-level data did not permit independent reassessment of germline status. Independent identical twins with iMCD shared homozygous NCOA4 p.G441E and monoallelic TRAF3 p.G502R variants but had different clinical courses, supporting a susceptibility or modifier model rather than monogenic causation. In a published macrophage RNA-seq study, NCOA4 depletion altered 293 transcripts at fold change >1.5 and FDR q < 0.05, enriched innate immune pathways, and produced predicted IL6 activation; IL6 was the only inflammatory upstream regulator reported with an activation z score >2.
Conclusions: Case level assessment placed the previously reported adverse outcome association within a plasma cell rich phenotype characterized by systemic fluid accumulation and organomegaly. Near heterozygous VAFs, together with subsequent germline NCOA4 observations, support continued evaluation of whether NCOA4 variation may also function as a susceptibility or disease modifying factor. We propose that NCOA4 variation may modify an iron stressed macrophage or myeloid niche that converges on IL-6 signaling and plasma cell expansion, rather than functioning as a uniform disease driver. Prospective paired germline and tissue sequencing, spatial localization of NCOA4, ferritin, hemosiderin, and IL-6, iron biomarker profiling, and functional testing of p.L261F and p.G441E are needed.
DISCLOSURES
Fnu Alnoor, MD: No relevant conflicts of interest to declare.